Suggested remit: To appraise the clinical and cost effectiveness of imlunestrant within its marketing authorisation for treating oestrogen receptor-positive, HER2-negative advanced breast cancer after endocrine treatment.
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Awaiting decision
- Process:
- STA Standard
- ID number:
- 6373
Email enquiries
If you have any queries please email TACommA@nice.org.uk
- External Assessment Group:
- Health Economics Research Unit and Health Services Research Unit, University of Aberdeen
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 June 2026 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 10 December 2025 | Note - Note added to the project documents |
| 30 September 2025 | Invitation to participate |
| 25 October 2024 | Note - Note added to the project documents |
| 11 June 2024 | Note added to the project documents |
| 25 April 2024 - 24 May 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6373 |
| 25 April 2024 | In progress. Scoping commencing |
| 25 October 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 25 October 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual